Sumitomo Mitsui Trust Group, Inc. 13D and 13G filings for Arcturus Therapeutics Holdings Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-11-05 06:07 am Purchase | 2024-09-30 | 13G | Arcturus Therapeutics Holdings Inc. ARCT | Sumitomo Mitsui Trust Group, Inc. | 2,315,294 8.560% | 994,642 (+75.31%) | Filing |
| 2024-02-05 06:08 am Sale | 2023-12-31 | 13G | Arcturus Therapeutics Holdings Inc. ARCT | Sumitomo Mitsui Trust Group, Inc. | 1,320,652 4.940% | -128,408 (-8.86%) | Filing |
| 2023-02-03 06:10 am Purchase | 2022-12-31 | 13G | Arcturus Therapeutics Holdings Inc. ARCT | Sumitomo Mitsui Trust Group, Inc. | 1,449,060 5.450% | 91,588 (+6.75%) | Filing |
| 2022-02-04 06:05 am Purchase | 2021-12-31 | 13G | Arcturus Therapeutics Holdings Inc. ARCT | Sumitomo Mitsui Trust Group, Inc. | 1,357,472 5.140% | 1,357,472 (New Position) | Filing |